Navigation Links
New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!
Date:10/2/2008

WESTON, Mass., Oct. 2 /PRNewswire/ -- Weston Medical Publishing today announced publication of the first issue of Journal of Neurodegeneration and Regeneration. (ISSN 1932-1481) This new peer-reviewed journal is designed to explore all aspects of neurodegeneration, neuroprotection and neuroregeneration including the molecular mechanisms, experimental approaches and their relevance in treating neurodegenerative disorders and neuroregenerative therapies.

When making the announcement, Publisher, Richard A. DeVito Jr. pointed out that while diagnosis may be the first step on the road of long term care for neurodegenerative patients, the pot of gold at the end of this difficult road will come from the challenging new frontier of neuroprotection and neuroregeneration research.

With the introduction of Journal of Neurodegeneration and Regeneration, (available online free of charge at http://ejournal.neuroregen.com until October 15th, 2008), the top neurospecialists worldwide will meet this challenge and bring to the medical community a long awaited exploration of the on-going research being conducted in this critical field.

Said DeVito, "The element of urgency couldn't be clearer. The numbers speak for themselves. In the United States alone, almost five million suffer from Alzheimer's disease; one million from Parkinson's disease; 400,000 from multiple sclerosis; and 30,000 from ALS. Worldwide, these four diseases account for more than 20 million patients."

"Further," he went on to say, "It is generally accepted that things are going to get worse before they get better. Aging greatly increases the risk of neurodegenerative disease and the average age of Americans and the worldwide populations are increasing. Today, over 37 million Americans alone are over the age of 65. Within the next 30 years this number is likely to double, putting more and more people at increased risk of neurodegenerative diseases."

"Research," DeVito noted, "will lead to better diagnosis, more effective treatments and, perhaps, cures for diseases like Alzheimer's, Parkinson's, multiple sclerosis, ALS and other diseases where few effective treatments and no cures are currently available."

The Journal of Neurodegeneration and Regeneration is guided by an international editorial review board of the foremost experts in the field under the leadership of co-Editors-in-Chief Dr. Philippe Taupin, PhD and Dr. Cathy Helgason, MD.

For manuscript submission or subscription information, visit the journal's Web page at http://www.neuroregen.com or contact the publisher, Weston Medical Publishing LLC, at 781-899-2702.

Contact: Richard A. DeVito, Jr.

Weston Medical Publishing

781-899-2702

radjr@pnpco.com


'/>"/>
SOURCE Weston Medical Publishing
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
3. Elsevier launches new journal: Stem Cell Research
4. Elsevier announces new journal on inflammatory bowel diseases
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
7. Good Clinical Practice Journal Awards: Winners Announced
8. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
9. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
10. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
11. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: